Vor Biopharma与RemeGen的交易为进入数十亿美元的自身免疫市场铺平了道路-动脉网

Vor Biopharma's RemeGen Deal Paves Way For Multiillion Dollar Autoimmune Market

benzinga 等信源发布 2025-06-30 14:31



可切换为仅中文







H.C. Wainwright

upgraded

升级

Vor Biopharma Inc.

生物制药公司

VOR

甚高频全向信标

, highlighting the company’s “rebirth” following the in-licensing of telitacicept.

，强调了公司因引进泰立西普（telitacicept）后实现的“重生”。

On Thursday, the company announced a strategic licensing agreement and a major capital raise to support its

周四，该公司宣布了一项战略许可协议和一笔重大资本筹集以支持其

push into autoimmune therapies

推动自身免疫疗法的发展

。

Vor Bio signed an exclusive global licensing deal with

Vor Bio 签署了一项全球独家许可协议与

RemeGen Co., Ltd.

荣昌生物制药公司

, giving it rights outside Greater China to develop and commercialize telitacicept, a dual-action fusion protein already approved in

，授予其在中国大陆以外地区开发和商业化双效融合蛋白泰利昔普的权利，该药物已在

China for multiple autoimmune disorders

中国对于多种自身免疫性疾病

。

Also Read:

另请阅读：

Why This Biotech Stock Just Doubled In A Single Day

为什么这只生物技术股票在一天之内翻了一番

Under the agreement, Vor will pay $125 million upfront, $45 million in cash, $80 million in stock warrants, and potential milestone payments exceeding $4 billion and tiered royalties.

根据协议，Vor公司将支付1.25亿美元的预付款，其中4500万美元为现金，8000万美元为股票认股权证，并可能支付超过40亿美元的里程碑款项以及分级特许权使用费。

The company also announced that

公司还宣布了

Jean-Paul Kress

让-保罗·克雷斯

has stepped in as CEO and Chairman, replacing

已接任首席执行官兼董事长，取代了

Dr. Robert Ang

罗伯特·安博士

, who will stay on as a strategic advisor through October.

，他将留任至十月的战略顾问。

Commenting on the development, HC Wainwright stated, “Overall, we are encouraged by the quick resurrection of the company by the board and the management as this transaction brings a de-risked asset that could be commercialized in the US starting mid-2028.”

HC Wainwright在评论此次进展时表示：“总体而言，我们对公司董事会和管理层迅速使公司重振感到鼓舞，因为这笔交易带来了一项风险较低的资产，有望从2028年年中开始在美国实现商业化。”

Analyst

分析师

Swayampakula Ramakanth

斯瓦扬帕库拉·拉马坎特

upgraded Vor Biopharma from Neutral to Buy on Monday with a

周一将Vor Biopharma的评级从“中性”上调为“买入”

price forecast of $3

3美元的价格预测

。

Ramakanth highlights the significant market opportunity for telitacicept in generalized myasthenia gravis (gMG). Based on a 2018 survey of Medicare data, an estimated 82,700 people in the U.S. had gMG in 2021, with approximately 75% receiving treatment.

拉马坎特强调了泰利塔西普在全身性重症肌无力（gMG）领域的重大市场机会。根据2018年对医疗保险数据的调查，估计2021年美国有82,700人患有全身性重症肌无力，其中约75%接受了治疗。

The analyst projects that if telitacicept is priced at $225,000 per patient yearly and captures 15% of the U.S. market, peak annual sales could reach $1.8 billion.

分析师预计，如果泰利西普每年每名患者的定价为 22.5 万美元，并且占据美国市场 15% 的份额，那么其年销售额峰值可能达到 18 亿美元。

Furthermore, the analyst says, should the drug successfully launch in the EU and Japan, with commercial partners managing sales outside the U.S. and achieving a 10% market share, it could generate an additional $2.7 billion in combined sales and royalties.

此外，分析师表示，如果该药物在欧盟和日本成功上市，由商业合作伙伴负责美国以外的销售，并获得10%的市场份额，那么它可能会带来额外27亿美元的销售额和特许权使用费。

While RemeGen is conducting a Phase 3 trial of telitacicept for lupus (SLE) in the U.S. and EU, the analyst notes that Vor Biopharma currently lacks a defined strategy for marketing the drug for SLE. Consequently, any potential sales from this indication are not factored into Vor’s current projections..

虽然荣昌生物正在美国和欧盟进行泰利西普针对狼疮（SLE）的三期临床试验，但分析师指出，Vor生物制药目前缺乏针对SLE销售该药物的明确策略。因此，该适应症可能带来的任何潜在销售额都未被纳入Vor当前的预测中。

Price Action:

价格行为：

VOR stock is up 49.1% at $1.58 at the last check on Monday.

周一最后一次检查时，VOR股票上涨49.1%，达到1.58美元。

加载中...